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SUMMARY 
We compared the number/percentages of naive and memory CD4+ T-cells, 
CD38+CD8+ T-cells and CD28+CD4+ and CD28+CD8+ T-cells in patients with 
advanced (baseline CD4+ count < 100) with those with less advanced (baseline CD4+ 
cell count > 100) HIV-disease during 4 years of suppressive HAART. This 
prospective, longitudinal study included 30 treatment-naive patients and 32 controls. 
Flow cytometry was done at baseline and after 1, 3, 6, 12, 24 and 48 months (mo). 
Advanced HIV-infected patients (n=13; median baseline CD4+: 23/µl) gained more 
CD4+ T-cells than less advanced patients (n=11; median baseline CD4: 189/µl) at 1 
mo (median: 60 vs 36/µl), 3 mo (86 vs 14), 6 mo (111 vs 23), 12 mo (174 vs 47), 24 
mo (162 vs 72) and 48 mo (257 vs 123) (p=0.15; p<0.001; p=0.026; p=0.021, p=0.1; 
p=0.06 respectively). Advanced patients gained relatively more naive CD4+ T-cells at 
48 mo compared to less advanced patients (27.3 vs 11.4%, p=0.05). The relative gain 
in memory CD4+ T-cells was greater in advanced versus less advanced patients at 1 
mo (median: 6.4 vs 1.4%), 3 mo (4.3 vs 2.0), 6 mo (6.7 vs 1.6), 12 mo (6.9 vs 2.4), 24 
mo (7.5 vs 3.1) and 48 mo (11.3 vs 6.8) (p=0.002; p=0.013; p<0.001; p=0.004; 
p=0.001; p=0.015, respectively). At 48 mo, CD38+CD8+ T-cells and naive CD4+ T-
cells reached normal values (9.2%, p=0.869 vs controls and 47.5%; p=0.699, 
respectively) in less advanced patients as well as CD38+CD8+ T-cells in advanced 
patients (4.7%, p=0.309 vs controls). The kinetics of naive and memory CD4+ T-cell 
reconstitution is different in less advanced compared to advanced HIV-patients.  
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INTRODUCTION 
 
 Human immunodeficiency virus type 1 (HIV-1) infection induces a 
progressive loss in the number of CD4+ T-cells, which is parallel to the development 
of severe immunodeficiency, increased susceptibility to opportunistic infection and 
subsequently death. The ability of highly active antiretroviral therapy (HAART) to 
reconstitute the immune system of HIV-infected patients is usually estimated by 
monitoring the increase in the number of CD4+ T-cells during viral suppression [1]. 
It has been hypothesised that in HIV-infected patients with undetectable 
viremia the number of CD4+ T-cells will increase for a certain period of time before 
reaching a plateau. This concept has been supported by several studies which 
demonstrated significantly slower increase in the number of CD4+ T-cell after the first 
or second year of treatment in virological responders [2-4]. Contrary to these findings, 
Hunt et al have recently provided evidence that CD4+ T-cell counts continue to rise 
after four years in people on continuously successful HAART, regardless of the 
baseline CD4+ T-cell value [5].  
The complete assessment of the quality of immune reconstitution during 
HAART does not only depend on the increase in the number of CD4+ T-cells but also 
includes monitoring the correction in virus-mediated changes in T-cell phenotype and 
function [6-13].  
The aim of this study was to compare the effect of four years of undetectable 
plasma viremia on the percentage of naive CD45RA+CD62L+ and memory CD45RO+ 
CD4+ T-cells, activated CD38+CD8+ T-cells and the expression of the costimulatory 
molecule CD28 on CD4+ and CD8+ T-cells in the peripheral blood of HIV-infected 
adults. We compared the kinetics of selected immune parameters between HIV-
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infected persons who began HAART with less than 100 CD4+ T-cells (advanced) and 
those who began therapy with higher CD4+ T-cell counts (moderately advanced). We 
limited our analysis to patients who become undetectable after 6 months of HAART 
and maintained <50 copies/ml during the follow-up period. 
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METHODS 
 
Study design and patients:  
 
This prospective, four-year longitudinal study was conducted at the University 
Hospital for Infectious Diseases "Dr. Fran Mihaljević", Zagreb, Croatia between the 
December of 1998. and November of 2002. We enrolled 30 treatment-naive HIV-1 
infected adults. HIV-patients were treated with a combination of zidovudine or 
stavudine, lamivudine and indinavir at standard doses. Included in this analysis were 
24 patients who become undetectable (less than 50 copies of HIV-1 RNA per ml of 
plasma) at 6 months and stayed so thereafter. 
Immunological (flow cytometry) and virological analysis (quantitative RT-
PCR for HIV-1 RNA) were done before and after 1, 3, 6, 12, 24 and 48 months of 
treatment. Plasma samples for HIV-1 RNA quantification and peripheral blood 
samples for flow cytometry were collected as a part of routine diagnostic follow-up.  
The study also included 32 apparently healthy controls. Informed consent was 
obtained from all patients and healthy controls. The study excluded children (< 17 
years of age) and pregnant women. The study was approved by the Ethics committee 
of the Hospital. 
 
Viral load 
 
The quantification of HIV-1 RNA in the plasma of HIV-1-infected persons 
was performed by using Cobas AmplicorTM HIV-1 monitor Test, version 1.5, 
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UltraSensitive specimen preparation (Roche Diagnostic Systems, Inc., Branchburg, 
New Jersey, USA) with lower limit of detection of 50 copies of HIV-1 RNA/ml.    
  
Flow cytometry  
 
To assess the quantity of T-cell immune reconstitution, we compared several 
lymphocyte subpopulations in HIV-1-infected patients before and during treatment to 
healthy controls. Percentage of CD28+CD4+ and CD28+CD8+ T-cells, naive 
CD45RA+CD62L+ and memory CD45RO+ CD4+ T-cells and activated CD38+CD8+ 
T-cells were determined by three-colour flow cytometry by using panel of 
monoclonal antibodies specific for CD3, CD4, CD8, CD14, CD16, CD19, CD45, 
CD56, HLA-DR, CD38, CD28, CD45RA, CD45RO and CD62L (DAKO, Denmark) 
conjugated with FITC, PE or RPE-Cy5. Absolute counts of CD4+ T-lymphocytes 
were determined directly on the cytometer by using Flow-Count Fluorospheres and 
four-colour flow cytometry panel CYTO-STAT tetra CHROME (CD45-FITC/CD4-
RD1/CD8-ECD/CD3-PC5 and CD45-FITC/CD56-RD1/CD19-ECD/CD3-PC5, 
Beckman Coulter, Inc., FL, USA) as recommended [14].  
Peripheral blood samples were prepared for flow cytometry by using a whole 
blood non-wash method on Multi-Q-Prep System with ImmunoPrep Reagent System 
(Beckman Coulter, Inc., FL, USA). The samples were analysed on Epics XL-MCL 
flow cytometer (Beckman Coulter, Inc., FL, USA).  
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Statistical analysis  
 
The changes in immunological parameters from baseline throughout the 
follow-up period were analysed by Wilcoxon signed rank test (p<0.05 was considered 
significant). The comparison between two independent groups was done by Mann-
Whitney test. All reported p-values are two-sided and exact. A generalized additive 
model was fit and trajectories of T-cell counts were described by drawing a smooth 
curve using robust local regression [15]. Statistical analysis was performed with SAS 
software version 8.2 [16] and StatXact release 5.0.3. (Cytel Software Corporation, 
USA). The loess option of PROC GAM was used to plot T-cells over time [16].   
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RESULTS:  
 
Patients 
Out of 30 patients enrolled, 24 met the inclusion criteria related to the 
undetectable viral load within 6 months of starting their first HAART regimen and 
completed all follow-ups. Pre-treatment viremia in 24 patients included in this 
analysis was 5.3 log10 copies of HIV-1 RNA/ml (range 3.4-6.7 log10 copies of HIV-1 
RNA/ml). After 3 months of HAART, plasma viremia was undetectable in 14 
patients. Ten out of 24 patients had detectable plasma viremia after 3 months of 
treatment (median 3.6 log10 copies of HIV-1 RNA/ml, range 3.0-4.8 log10 copies of 
HIV-1 RNA/ml) but subsequently achieved undetectable plasma viremia after 6 
months of HAART.     
The patients were divided into two groups, based on their initial CD4+ T-cell 
counts (< or > 100 cells/µl). HIV-infected patients with < 100 CD4+ T-cells per µl 
before treatment (n=13) were considered advanced (Table 1). At baseline, median 
percentages of naive and memory CD4+ T-cells in advanced patients were 0.9% and 
2.1%, respectively. Patients with initial CD4+ T-cell counts > 100 cells per µl (n=11) 
were classified as moderately advanced. Median baseline percentages of naive and 
memory CD4+ T-cells in moderately advanced patients were 32.6% and 10.1%, 
respectively.  
 
Absolute counts of CD4+ T-cells 
 Absolute counts of CD4+ T-cells in advanced HIV-infected patients increased 
from a median of 23 cells/µl (IQR 4-55) before treatment to a median of 298 cells/µl 
(IQR 188-322) after 4 years of HAART (Table 2). Following an initial rapid increase 
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in CD4+ T-cell counts in the first three months of treatment, there continued to be a 
less marked but sustained increase in median CD4+ T-cell count during the remainder 
of the first year. There were statistically significant increases in the CD4+ T-cell 
counts at the end of the first and fourth year of treatment. 
  In less advanced patients, CD4+ T-cell counts increased from a median of 189 
cells/µl (IQR 164-225) before treatment to 341 cells/µl (IQR 260-495) after 4 years of 
treatment (Table 2). The changes in CD4+ T-cell counts in moderately advanced 
patients were more gradual compared with advanced patients.  
Advanced HIV-infected patients gained more CD4+ T-cells than less advanced 
patients at 1 month (median: 60 vs 36 cells/µl), 3 months (86 vs 14 cells/µl), 6 months 
(111 vs 23 cells/µl), 12 months (174 vs 47 cells/µl), 24 months (162 vs 72 cells/µl) 
and 48 months (257 vs 123 cells/µl) (p=0.15; p<0.001; p=0.026; p=0.021, p=0.1; 
p=0.06, respectively, Table 2, Figure 1).  
 
Naive CD4+ T-cells 
 Percentages of naive CD4+ T-cells increased in advanced patients increased 
from baseline (median 0.9%, IQR 0-15%) to a median of 40.2% (IQR 37.0-45.6%) 
after 48 months of treatment (Table 3). There was an early and statistically significant 
increase in naive CD4+ T-cells within 3 months of HAART followed by the period of 
little change until the end of the first year. Significant changes in naive CD4+ T-cells 
were also observed at the end of the second year of treatment but with little change 
thereafter.    
In less advanced patients, naive CD4+ T-cells increased from a median 32.6% 
(IQR 21.2-48.7%) at baseline to 50.6% (IQR 38.9-56.9%) after 48 months of HAART 
(Table 3). Unlike advanced HIV-patients, there was no early (first 3 months) increase 
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in naive CD4+ T-cells in moderately advanced patients. Significant increase in the 
percentage of naive CD4+ T-cells in moderately advanced patients was observed 
between the third and sixth month of treatment but we failed to observe any additional 
increase until the end of the first year. Percentage of naive CD4+ T-cells in 
moderately advanced patients increased significantly at the end of the second and 
third year of treatment. At 48 months, percentages of naive CD4+ T-cells in less 
advanced patients (median 50.6%) reconstituted to the levels of healthy controls 
(median 47.5%, p=0.699).  
Advanced patients gained relatively more naive CD4+ T-cells at 48 months 
compared to less advanced patients (27.3 vs. 11.4%, p=0.05, Figure 2).  
 
Memory CD45RO+ T-cells 
 Suppressive HAART enabled an increase in memory CD4+ T-cells in 
advanced HIV-infected patients from baseline median 2.1% (IQR 5.0-6.9%) to a 
median of 15.6% (IQR 12.0-20.5%) after 48 months (Table 3). Following an initial 
rapid and significant increase within the first month of treatment, percentages of 
memory CD4+ T-cells slightly decreased during the next two months with little 
change until the second significant increase observed at the end of the fourth year of 
HAART.   
 In less advanced patients, percentages of memory CD4+ T-cells increased 
from a baseline median 10.1% (IQR 6.6-13.0%) to a median 17.8% (IQR 16.5-20.1%) 
at the end of follow-up (Table 3). Similarly to advanced patients, an early and 
statistically significant increase in memory CD4+ T-cells occurred during the first 
month of HAART. There was a period of sustained but not significant increase in 
memory CD4+ T-cells during the remainder of the first year as well as during the 
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second year of HAART followed by the significant increase at the end of the follow-
up.  
The relative gain in memory CD4+ T-cells was greater in advanced versus less 
advanced patients at 1 month (median: 6.4 vs 1.4%), 3 months (4.3 vs 2.0%), 6 
months (6.7 vs 1.6%), 12 months (6.9 vs 2.4%), 24 months (7.5 vs 3.1%) and 48 
months (11.3 vs 6.8%) (p=0.002; p=0.013; p<0.001; p=0.004; p=0.001; p=0.015, 
respectively, Figure 3). 
 
CD8+ T-cells 
Four years of HAART had little influence on the percentages of CD8+ T-cells 
in both advanced and moderately advanced patients. Percentages of CD8+ T-cells in 
advanced HIV-infected patients slightly decreased from a median of 57.1% (IQR 
43.5-63.0%) before treatment to a median of 51.0% (IQR 44.9-56.7%) after 4 years of 
treatment (Table 2.). In less advanced HIV-infected patients, percentages of CD8+ T-
cells also decreased from a pre-treatment median of 58.0 (IQR 44.5-63.7) to 48.1% 
(IQR 43.1-50.5%) after 48 months of HAART (Table 2.). 
 
Other lymphocyte subpopulations 
There was no difference in the kinetics of CD38+CD8+ T-cells, CD28+CD4+ 
and CD28+CD8+ T-cells between advanced and less advanced patients during follow-
up.   
 HAART-induced suppression of viral replication enabled a decrease in the 
percentage of activated CD38+CD8+ T-cells in advanced HIV-infected patients from a 
pre-treatment median of 50.0% (IQR 45.3-51.3%) to 4.7% (IQR 3.1-11.7%) after 48 
months (Table 2). Percentages of CD38+CD8+ T-cells in less advanced patients 
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decreased from baseline median of 47.7% (IQR 40.2-51.0%) to 9.2% (IQR 6.5-
12.6%) (Table 2). 
 The most dramatic decrease in the percentage of CD38+CD8+ T-cells in both 
patient groups occurred within the first month of HAART. In moderately advanced 
patients, statistically significant decrease in the percentages of these cells was 
observed during the first six months of treatment. Initial rapid decrease in the 
percentages of CD38+CD8+ T-cells was parallel to the treatment-induced reduction of 
plasma viremia to undetectable levels in 10 out of 24 patients after 3 months and all 
patients after 6 months of HAART (inclusion criteria). Percentages of CD38+CD8+ T-
cells showed little change between the sixth month of HAART and the remainder of 
the first year. Interestingly, percentages of CD38+CD8+ T-cells decreased even further 
at the end of the second and fourth year of suppressive HAART.  At month 48, 
CD38+CD8+ T-cells reached normal values (median 9.2% for controls) in both 
advanced (4.7%, p=0.309 vs. controls) and less advanced patients (9.2, p=0.869 vs. 
controls).  
 Percentages of CD4+ T-cells expressing costimulatory molecule CD28 
increased from baseline median of 60.2% (IQR 56.0-75.0%) before treatment to a 
median of 90.1 (IQR 80.9-93.6%) after 48 months of HAART (Table 3). 
Antiretroviral treatment appeared to have little influence on the percentages of CD4+ 
T-cells expressing a costimulatory molecule CD28 during the first year in advanced 
patients. The majority of increase in the percentages of CD28+CD4+ T-cells in 
advanced patients occurred during the second and fourth year of treatment.   
In less advanced patients, percentages of CD28+CD4+ T-cells increased from 
pre-treatment median of 59.1% (IQR 45.1-85.9%) to a median of 89.5% (IQR 80.5-
91.8%) after 48 months of HAART (Table 3). Similarly to advanced patients, a period 
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of little change during the first six months of treatment was followed by statistically 
significant increases in the percentage of these cells at the end of the first, second and 
fourth year of HAART.  
Percentages of CD8+ T-cells expressing costimulatory molecule CD28 in 
advanced patients increased from baseline median of 39.6% (IQR 19.6-44.8%) before 
treatment to a median of 73.0 (IQR 70.6-75.6%) after 48 months of HAART (Table 
3). Statistically significant increase in the percentages of CD28+CD8+ T-cells was 
observed within the first month of treatment as well as at the end of the second and 
fourth year.  
In less advanced patients, percentages of CD28+CD8+ T-cells increased from 
baseline median of 34.3 (IQR 25.1-50.1%) to a median of 69.5% (IQR 64.5-75.9%, 
Table 3). Similarly to advanced patients, percentages of these cells significantly 
increases within the first month of treatment. After a 2 month period of little change, 
percentages of CD28+CD8+ T-cells continued a statistically significant increase at all 
time intervals until the end of follow-up.  
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DISCUSSION 
Our results have shown that the kinetics of HAART-induced increase in truly 
naive and memory subpopulations of CD4+ T-cells is different in moderately 
advanced compared to advanced HIV-infected patients. Advanced HIV-infected 
patients had a more pronounced gain in the percentage of memory CD4+ T-cells 
during the first and at the end of the second and fourth year of HAART compared to 
less advanced patients. In addition, the relative gain in naive CD4+ T-cells was also 
significantly higher in advanced compared to moderately advanced HIV-patients after 
four years of HAART. After four years of suppressive HAART enabled the complete 
reconstitution of naive CD4+ T-cells in less advanced but not in advanced patients. 
Additionally, long-term control of viral replication enabled the decrease of activated 
CD38+CD8+ T-cells to the levels of healthy controls.   
 The reason for the observed difference in the gain of memory CD4+ T-cells in 
advanced vs. less advanced HIV-infected patients during suppressive HAART is not 
clear. A model of T-cell reconstitution as a composite of memory cell redistribution 
from lymphoid tissues to the periphery and a regeneration of naive T-cells from 
thymic origin provides a possible explanation for the observed difference [17]. The 
kinetics of memory CD4+ T-cells observed in this study appeared to be triphasic: an 
early and rapid increase followed by the more gradual increased and a subsequent 
significant increase at the end of follow-up.  The initial increase in the percentage of 
these cells probably corresponds to the redistribution phase of memory T-cell from 
lymphoid tissues to the peripheral blood.  
 It is believed that the amount of memory T-cells “entrapped” in the peripheral 
lymphoid tissues is much higher in advanced HIV-disease compared with 
asymptomatic patients or those with early HIV-disease. Therefore, the number of 
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memory T-cells migrating to the periphery upon HAART initiation is expected to be 
much higher in advanced patients and this could explain the observed difference in 
memory CD4+ T-cell gains between our two patient groups.  
 According to a different model of CD4+ T-cell depletion during HIV infection 
being a result of disturbed homeostasis, it is possible that the homeostatic pressure to 
compensate for the loss of this cellular subpopulation was more pronounced in 
patients with lower pre-treatment CD4+ T-cells count [18]. 
Naive CD4+ T-cells are often regarded as a measure of true immune 
reconstitution because they enable a diversification of T-cell receptor repertoire in the 
infected host. Our study has shown that a complete restoration of naive CD4+ T-cells 
after four years of successful virological control only in less advanced patients. Our 
study has also shown an early increase in naive CD4+ T-cells of advanced patients, 
similarly to that observed by Mezzaroma et al [19]. The importance of naive CD4+ T-
cell in long-term immunological recovery during HAART was also confirmed by 
Notermans et al. showing that long term increase in total CD4+ T-cells was predicted 
on the baseline number of naive CD4+ T-cells [20].  
Literature data on the gain in the number of CD4+ T-cells during suppressive 
HAART in longitudinal studies is quite variable [3,4,5,21,22]. Lederman et al 
monitored CD4+ T-cell increase in 643 HIV-infected patients during 144 weeks and 
demonstrated [22]. According to their results, CD4+ T-cells increased from pre-
treatment median of 266 CD4+ T-cells/µl to a median of 358 cells/µl at the end of 
follow-up, showing similar kinetics of CD4+ T-cell reconstitution to that observed in 
our study. 
The ability of the immune system to continuously reconstitute CD4+ T-cells 
for longer periods of time is still a controversial issue. The results of several 
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longitudinal studies suggested that the ability of the immune system to continuously 
reconstitute total CD4+ T-cells for more than one or two years was limited [2,3,4]. A 
recent study by Hunt et al showed that virological responders to HAART continue to 
increase their CD4+ T-cell count even after four years of treatment, regardless of the 
initial CD4+ T-cells count [5]. However, this view was contradicted by Viard et al 
(2004) who failed to demonstrate any significant gain in CD4 T-cells by prolonging 
HAART for more than three years and questioned the value of life-long HAART [21].  
The results of our study have show a continuous increase in the number of 
CD4+ T-cells between the second and fourth year of HAART in both advanced and 
moderately advanced HIV-infected patients. Unfortunately, we were not able to 
analyse the selected parameters after three years of HAART. Therefore, we do not 
know it this was a difference between the second and third or third and fourth years of 
HAART. Therefore, we can not claim that the immune reconstitution continues for 
four years without reaching a plateau.  
The ability of HAART to correct virus-induced downregulation of a 
costimulatory molecule CD28 on CD4+ and CD8+ T-cells has been described 
previously [3, 23]. Arno et al have shown a normalisation in the expression of CD28 
on CD8+ T-cells in nine HIV-1-infected asymptomatic persons treated with 
monotherapy or double antiretroviral therapy who maintained undetectable plasma 
viremia for two years [23]. Valdez et al observed the complete reconstitution of CD28 
on CD8+ T-cells but not on CD4+ T-cell in patients who began treatment in 
moderately advanced HIV-disease after three years of HAART [3]. However, our 
study has shown that four years of HAART were not sufficient to completely 
reconstitute the expression of CD28 on CD4+ and CD8+ T-cells in both less advanced 
and advanced HIV-infected patients. 
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Sousa et al have proposed a concept concerning the role of immune 
hyperactivation as an inducer of CD4+ T-cells depletion in HIV-disease [24]. 
Therefore, a reduction in the expression of activation markers such as CD38 (on CD8+ 
T-cells) is considered to be an essential part of immune reconstitution. Valdez et al 
have shown that three years of HAART did not completely abrogate abnormal CD8+ 
T-cell activation in moderately advanced HIV-disease. However, our study has shown 
a complete normalisation of CD38 overexpression on CD8+ T-cell after four years of 
HAART in both moderately advanced and advanced HIV-infected persons. 
Both groups of HIV-infected persons included in our study showed the highest 
reduction in the percentage of CD38+CD8+ T-cells within the first month of treatment 
which is probably related to the marked decrease in the plasma viremia observed in 
that period of time. HAART-mediated decrease in the expression of CD38 on CD8+ 
T-cells parallel to the reduction in the plasma viremia has been previously described 
[25]. Additionally, both groups of HIV-infected persons included in the study 
(regardless of their initial CD4+ T-cell counts) demonstrated a significant decrease in 
the percentage of CD38+CD8+ T-cells after two and four years of HAART.  
 In summary, this study indicates that the kinetics of the reconstitution of CD4+ 
T-cells, naive and memory CD4+ T-cells induced by HAART might be different in 
patients with more advanced HIV-infection compared to those with less advanced 
disease. The pattern was similar, however the magnitude of the response compared to 
the baseline value was different at various time points. There was no difference in the 
pattern or magnitude of CD38+CD8+ T-cells as well as in CD28+CD4+ and 
CD28+CD8+ T-cells between patients with less than 100 CD4+ T-cells compared to 
those with more than CD4+ T-cells/µl.  
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Table 1. Baseline demographic and immunological parameters of the study population 
Parameter Healthy 
controls 
advanced HIV-
patients  
(baseline CD4+ T-
cell count  
< 100 cells/µl) 
moderately advanced 
HIV-patients 
(baseline CD4+ T-
cell count > 100 
cells/µl) 
Number 24 13 11 
Age in years 37.5  
(31-44) 
36  
(34-42) 
41  
(28-44) 
Sex ratio 
(Male/Female) 
20/4 10/3 10/1 
CD4+ T-cells/µl 936.5 
(785.5-1123) 
23 
(4-55) 
189  
(164-225) 
 CD4+ T-cells 
(%) 
47.3 
(42.8-49.7) 
2.6  
(0.7-6.1) 
15,6 
(11.8-19.7) 
CD45RA+CD62L+ 
CD4+ T-cells (%) 
47.5 
(41.6-52.3) 
 
0.9 
(0-15) 
32.6 
(21.2-48.7) 
CD45RO+CD4+  
T-cells (%) 
23.3 
(21.3-25.9) 
2.1 
(5.0-6.9) 
10.1 
(6.6-13.0) 
CD8+ T-cells (%) 21.6 
(16.7-25.8) 
57.1 
(43.5-63.0) 
58.0 
(44.5-63.7) 
CD38+CD8+ T-cells 
(%) 
9.2 
(7.0-11.0) 
50.0 
(45.3-51.5) 
47.7 
(40.2-51.0) 
CD28+CD4+ T-cells 95.6 60.2 59,1 
 24 
(% of total CD4+ T-
cells) 
(93.5-97.1) (56.0-75.0) (45.1-85.9) 
CD28+CD8+ T-cells 
(% of total CD8+ T-
cells) 
77.0 
(75.0-85.6) 
39.6 
(19.6-44.8) 
34.4 
(25.1-50.1) 
 
-values expressed as median, values in parentheses are interquartile range (IQR) 
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Table 2.  Number of CD4+  T-cells and percentages of, CD8+ and CD38+ CD8+ T-cells 
in uninfected healthy controls and, advanced and moderately advanced HIV infected 
patients before and after 1, 3, 6, 12, 24 and 48 months of highly active antiretroviral 
therapy. 
 
 Advanced patients 
(N=13) 
Moderately 
advanced patients 
(N=11) 
Pa Pb 
Treatment time 
points (months) 
Median (IQR) Median (IQR)   
CD4+ T-cells 
(cells/µl) 
    
0 23 (4-55) 189 (164-225)   
1 72*** (59-205) 213 (200-256) 0.15  
3 123* (82-201) 216 (171-241) <0.00
1 
 
6 125 (107-205) 221 (200-299) 0.026  
12 215** (104-235) 242 (211-336) 0.021  
24 237 (115-262) 301 (326-387) 0.1  
48 298** (188-322) 314 (260-495) 0.06  
Controls 936.5 (785.5-1123)  <0.0001 
CD8+ T-cells %     
0 57.1 (43.5-63.0) 58.0 (44.5-63.7)   
1 48.7 (42.3-60.6) 56.5 (43.6-59.7) NS  
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3 50.4 (45.7-60.1) 54.6 (42.9-60.4) NS  
6 54.4 (44.7-59.4) 53.2 (45.5-61.3) NS  
12 55.2 (44.7-58.2) 51.3 (46.9-60.1) NS  
24 51.2 (45.1-55.2) 50.9* (48.3-55.6) NS  
48 51.0 (44.9-56.7) 48.1** (43.1-50.5) NS  
Controls 21.6 (16.7-25.8)  <0.0001 
CD38+CD8+  
T-cells % 
    
0 50.0 (45.3-51.5) 47.7 (40.2-51.0)   
1 28.0* (21.4-36.9) 32.2* (29.1-36.1) NS  
3 29.8 (17.0-32.0)  21.9* (20.0-28.3) NS  
6 21.0 (18.5-25.3) 19.5* (17.6-23.2) NS  
12 17.0 (14.5-22.2) 17.3 (13.2-19.0) NS  
24 10.1*** (8.6-16.9) 11.0** (8.9-14.6) NS  
48 4.7* (3.1-11.7) 9.2* (6.5-12.6) NS  
Controls 9.2 (7.0-11.0)  0.44 
(0.42-
0.45) 
 
Statistically significant increase from the previous measurement are marked 
*(p<0.05), ** (p<0.01) and *** (p<0.001); Wicoxon signed ranked test. 
aBetween group comparisons of the difference of values at particular time points and 
the baseline value. 
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bComparison between values after 48 months of treatment in moderately and 
advanced HIV infected patients and healthy controls using the Kruskal-Wallis test  
with Monte Carlo estimations of exact p-values and their 99% CI. 
IQR, interquartile range; NS, not significant. 
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Table 3. Percentages of CD28+ CD4+ ,CD28+ CD8+ T,  CD45RO+CD4+ and 
CD45RA+CD62L+  T cells in uninfected healthy controls and, advanced and 
moderately advanced HIV infected patients before and after 1, 3, 6, 12, 24 and 48 
months of highly active antiretroviral therapy. 
 
 Advanced 
patients 
(N=13) 
Moderately 
advanced patients 
(N=11) 
Pa Pb 
Treatment time points 
(months) 
Median (IQR) Median (IQR)   
CD28+CD4+ T-cells     
0 60.2 (56.0-75.0) 59.1 (45.1-85.9)   
1 74.0 (58.9-86.7) 70.1 (60.2-85.6) NS  
3 76.2 (60.1-85.0) 73.4 (64.5-87.6) NS  
6 77.7 (60.1-88.8) 79.7 (60.3-82.3) NS  
12 76.6 (64.5-81.3) 85.2** (74.5-89.7) NS  
24 83.2*** (70.9-
90.1) 
88.1* (77.8-89.6) NS  
48 90.1* (80.9-93.6) 86.9** (80.5-91.8) NS  
Controls 95.6 (93.5-97.1)  <0.0001 
CD28+CD8+ T-cells     
0 39.6 (19.6-44.8) 34.4 (25.1-50.1)   
1 40.6* (35.0-52.1) 42.4** (30.1-52.3) NS  
3 44.3 (37.7-47.8) 43.6 (30.1-52.3) NS  
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6 45.4 (39.5-51.0) 49.8** (39.1-60.1) NS  
12 45.8 (41.4-88.1) 57.6* (45.6-64.5) NS  
24 59.6** (55.6-
64.5) 
59.6* (55.6-65.6) NS  
48 73.0*** (70.6-
75.6) 
69.5* (64.5-75.9) NS  
Controls 77.0 (75.0-86.0)  <0.0001 
CD45RO+CD4+ T-
cells 
    
0 2.1 (5.0-6.9) 10.1 (6.6-13.0)   
1 9.5*** (5.2-11.5) 10.6** (8.1-15.2) 0.002  
3 8.3 (5.2-13.2)  12.3 (7.9-15.3) 0.013  
6 9.1 (6.9-12.5) 12.5 (7.6-14.0) <0.00
1 
 
12 10.2 (3.3-12.9) 13.2 (9.5-13.6) 0.004  
24 10.4 (9.6-11.2)  13.6 (11.0-14.5) 0.001  
48 15.6** (12.0-
20.5) 
17.8** (16.5-20.1) 0.015  
Controls 23.3 (21.3-26.0)  <0.0001 
CD45RA+CD62L+ 
CD4+ T-cells 
    
0 0.9 (0-15) 32.6 (21.2-48.7)   
1 20.1* (18.5-20.6) 35.2 (20.1-45.6) NS  
3 22.3** (18.9- 40.1 (22.6-50.2) NS  
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24.6) 
6 21,5 (19.2-24.6)  38.0* (20.6-54.6) NS  
12 25.9** (20.4-
30.8) 
39.8 (22.3-54.2) NS  
24 33.2* (27.7-36.8) 40.5* (25.6-55.1) NS  
48 40.2 (37.0-45.6) 50.6* (38.9-56.9) 0.05  
Controls 47.5 (52.3-41.6)  0.056 
(0.05-
0.06) 
 
Statistically significant increase from the previous measurement are marked 
*(p<0.05), ** (p<0.01) and *** (p<0.001); Wicoxon signed ranked test. 
aBetween group comparisons of the difference of values at particular time points and 
the baseline value. 
bComparison between values after 48 months of treatment in moderately and 
advanced HIV infected patients and healthy controls using the Kruskal-Wallis test 
with Monte Carlo estimations of exact  p-values and their 99% CI. 
IQR, interquartile range; NS, not significant. 
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Figure 1. Loess estimates differences of CD4+ T-cell counts 
 
Figure 2. Loess estimates differences of percentage of memory CD4+ T-cells 
 
Figure 3. Loess estimates differences of percentage of naive CD4+ T-cells 
